Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › NCT05584631

IVIG vs SCIG in CIDP

The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

* Patients aged \>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria).
* 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG.

Exclusion Criteria:

* Patients receiving IVIG for indications other than CIDP will be excluded.
* Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \< 50 mL/min) will be excluded
* Active malignancies
* Diabetes
* Myasthenia gravis
* Immunodeficiency
* Autoimmune disease

About the study

Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.

What is being tested

• Intravenous immune globulin G (drug)
• Subcutaneous immune globulin G (drug)

Sponsor: Rutgers, The State University of New Jersey · Participants: 20 · Started: Sep 11, 2022

Contact the study team

• Luigi Brunetti, PhD · Phone: 2016385868

Official record on ClinicalTrials.gov — NCT05584631

Locations in the U.S.

Conditions

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Agammaglobulinemia
• Obesity

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.